Correction
for
Braunwald et al., J Am Coll Cardiol 36 (3) 970-1062.
Corrections
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970–1062.
The following errors need to be corrected:
Table 6, Page 979, "Low Risk" column, first line of first entry. The words "or progressive" should be added to the entry after "New-onset" to read, "New-onset or progressive CCS Class III or IV angina in the past 2 weeks without prolonged (>20 min) rest pain but with moderate or high likelihood of CAD (see Table 5)."
"High Risk" column, "Cardiac markers" row, first line in entry. Delete "markedly" to read "Elevated (e.g., TnT or TnI >0.1 ng/mL)."
The corrected table with legend appears below:
Table 11, Page 995, "Dose/Dosage" column, entry for intravenous nitroglycerin. Replace mg/min with µg/min to read 5–200 µg/min.
The corrected table with legend appears below:
Page 1006, first column, 2nd paragraph, 6th line. Delete the word "reduced" and the word dalteparin should be substituted for the word enoxaparin (7th line).
The full paragraph should read:
The FRISC, FRIC, TIMI 11B, and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) trials evaluated the potential benefit of the prolonged administration of an LMWH after hospital discharge. The first 3 of these trials did not show a benefit of treatment beyond the acute phase. In the FRISC trial, doses of dalteparin were administered between 6 days and 35 to 45 days; in FRIC, patients were rerandomized after the initial 6-day treatment period to receive dalteparin for an additional 40 days; and the outpatient treatment period lasted 5 to 6 weeks in TIMI 11B and 1 week in the FRAXIS trial. The FRISC II trial used a different study design. Dalteparin was administered to all patients for a minimum of 5 days (223). Patients were subsequently randomized to receive placebo or the continued administration of dalteparin twice a day for up to 90 days. Analysis of the results from the time of randomization showed a significant reduction with dalteparin in the composite end point of death or MI at 30 days (3.1% vs. 5.9%, p = 0.002) but not at 3 months (6.7% vs. 8.0%, p = 0.17). The composite of death, MI, or revascularization during the total treatment period was reduced at 3 months (29.1% vs. 33.4%, p = 0.031). The benefits of prolonged dalteparin administration were limited to patients who were managed medically and to patients with elevated TnT levels at baseline. These results may make a case for the prolonged use of an LMWH in selected patients who are managed medically or in whom angiography is delayed.
Figure 10, Page 1009, first column, "All" graph. "3.9%" should be changed to "2.9%."
View larger version (28K):
[in this window]
[in a new window]
|
Figure 10 Kaplan-Meier curves showing cumulative incidence of death or MI in patients randomly assigned to platelet GP IIb/IIIa receptor antagonist (bold line) or placebo. Data are derived from the CAPTURE, PURSUIT, and PRISM-PLUS trials (248). Left, Events during the initial period of medical treatment until the moment of PCI or CABG. In the CAPTURE trial, abciximab was administered for 18 to 24 h before the PCI was performed in almost all patients as per study design; abciximab was discontinued 1 h after the intervention. In PURSUIT, a PCI was performed in 11.2% of patients during a period of medical therapy with eptifibatide that lasted 72 h and for 24 h after the intervention. In PRISM-PLUS, an intervention was performed in 30.2% of patients after a 48-h period of medical therapy with tirofiban, and the drug infusion was maintained for 12 to 24 h after an intervention. Right, Events occurring at the time of PCI and the next 48 h, with the event rates reset to 0% before the intervention. CK or CK-MB elevations exceeding 2 times the upper limit of normal were considered as infarction during medical management and exceeding 3 times the upper limit of normal for PCI-related events. Adapted from Boersma et al. (248), CAPTURE (182), PURSUIT (10), and PRISM-PLUS (21).
|
|
The corrected figure with legend appears below:
This article has been cited by other articles:
|
|
|
|
 
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
631 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Steinhart
Acute coronary syndromes
Can. Med. Assoc. J.,
November 23, 2004;
171(11):
1322 - 1322.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Harrington and E. Magnus Ohman
Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: Has the time come for 'drive-through' angiography?
Eur. Heart J.,
February 1, 2002;
23(3):
191 - 194.
[Full Text]
[PDF]
|
|
|
|
